4.5 Article

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

Journal

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 15, Issue -, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359231183680

Keywords

efficacy; encequidar; HM30181A; oral paclitaxel; P-gp inhibitor; pharmacokinetics; safety

Categories

Ask authors/readers for more resources

This study investigated the pharmacokinetics, overall response rate, and safety of weekly oral paclitaxel with encequidar in patients with advanced breast cancer. The results showed that the combination therapy produced consistent therapeutic plasma paclitaxel exposure and had a high clinical benefit rate, with a low rate of neurotoxicity.
Background:Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous form. Encequidar (E) is a first-in-class, minimally absorbed, gut-specific oral P-gp inhibitor that facilitates the oral absorption of paclitaxel. Objectives:To investigate the pharmacokinetics (PK), overall response rate (ORR), and safety of weekly oral paclitaxel with encequidar (oPAC + E) in patients with advanced breast cancer. Design:This is a multicenter, single-arm, open-label study in six medical centers in Taiwan. Methods:Patients with advanced breast cancer were administered 205 mg/m(2) oPAC and 12.9 mg E for 3 consecutive days weekly for up to 16 weeks. Plasma samples were collected at weeks 1 and 4. PK, ORR, and safety were evaluated. Results:In all, 28 patients were enrolled; 27 had MBC; 23 had prior chemotherapy; and 14 had & GT;2 lines of prior chemotherapy. PK were evaluable in 25 patients. Plasma paclitaxel area under the curve (AUC)((0-52 h)) at week 1 (3419 & PLUSMN; 1475 ng h/ml) and week 4 (3224 & PLUSMN; 1150 ng h/ml) were equivalent. Best overall response in 28 evaluable patients was partial response (PR) in 11 (39.3%), 13 (46.4%) stable disease (SD), and 1 (3.6%) with progressive disease (PD). No patient achieved complete response (CR). The clinical benefit rate (CR + PR + SD) was 85.7%. Major adverse events among the 28 treated patients were grade 3 neutropenia (25%), grade 4 neutropenia (18%), with febrile neutropenia in 4%, and grade 3 diarrhea (4%). No treatment-related deaths occurred. Grade 2 peripheral neuropathy occurred in 1 (4%) patient and grade 3 peripheral neuropathy in 1 (4%) patient. Conclusions:oPAC + E produced a consistent therapeutic plasma paclitaxel exposure during treatment. There was a high rate of radiologically assessed clinical benefit, and a low rate of neurotoxicity which may provide advantages over IV paclitaxel. Registration:ClinicalTrials.gov Identifier: NCT03165955

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available